Generic Name and Formulations:
Atovaquone 750mg/5mL; oral susp; citrus flavor.
Indications for MEPRON:
Treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in patients intolerant to trimethoprim/sulfamethoxazole (TMP/SMX). Prevention of PCP in patients intolerant to TMP/SMX.
Limitations Of use:
Treatment of more severe PCP has not been studied. Mepron's efficacy has not been studied in those who are failing therapy with TMP/SMX.
Take with food. ≥13yrs: Treatment: 750mg twice daily for 21 days. Prophylaxis: 1500mg once daily.
<13yrs: not established.
GI disorders or inability to take with food. Monitor in severe hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
Concomitant rifampin or rifabutin: not recommended. Antagonized by tetracycline; caution and monitor if use is needed. May be antagonized by metoclopramide (use only if other antiemetics are not available). Antagonizes indinavir; caution and monitor if use is needed.
Diarrhea, rash, headache, nausea, fever, rhinitis, vomiting, sweating, flu syndrome, sinusitis, pruritus, insomnia, depression, myalgia.
Neurology Advisor Articles
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- A Convenient Truth: The Problem With Seizure Under-Reporting and How to Fix It
- Incidence of Serotonin Syndrome With Co-Prescription of Triptans, Antidepressants
- Idiopathic Parkinson Disease May Increase Risk for Overactive Bladder
- Palliative Care in Movement Disorders: Recommendations for Improvement
- Cannabinoids May Be Effective as Adjunctive Treatment for Refractory Epilepsy